Guselkumab (an IL-23–specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis by Sofen, Howard, MD, Smith, Stacy, MD, Matheson, Robert T., MD, Leonardi, Craig L., MD, Calderon, Cesar, PhD, Brodmerkel, Carrie, PhD, Li, Katherine, MS, Campbell, Kim, PhD, Marciniak, Stanley J., MBA, Wasfi, Yasmine, MD, PhD, Wang, Yuhua, PhD, Szapary, Philippe, MD, Krueger, James G., MD, PhD

Get full text

Evaluation of disease-mediated therapeutic protein-drug interactions between an anti-interleukin-6 monoclonal antibody (sirukumab) and cytochrome P450 activities in a phase 1 study... by Zhuang, Yanli, de Vries, Dick E., Xu, Zhenhua, Marciniak Jr, Stanley J., Chen, Dion, Leon, Francisco, Davis, Hugh M., Zhou, Honghui

Get full text

First-in-human study to assess guselkumab (anti-IL-23 mAb) pharmacokinetics/safety in healthy subjects and patients with moderate-to-severe psoriasis by Zhuang, Yanli, Calderon, Cesar, Marciniak, Stanley J, Bouman-Thio, Esther, Szapary, Philippe, Yang, Tong-Yuan, Schantz, Allen, Davis, Hugh M., Zhou, Honghui, Xu, Zhenhua

Get full text

Pharmacokinetic Bridging Approach for Developing Biologics-delivery Devices: A Case Study With a Golimumab Autoinjector by Xu, Zhenhua, PhD, Marciniak, Stanley J., MBA, Frederick, Bart, Kim, Lilianne, PhD, Zhuang, Yanli, PhD, Davis, Hugh M., PhD, Zhou, Honghui, PhD

Get full text

Pharmacokinetics and Safety of Golimumab, a Fully Human Anti-TNF-α Monoclonal Antibody, in Subjects With Rheumatoid Arthritis by Zhou, Honghui, Jang, Haishan, Fleischmann, Roy M., Bouman-Thio, Esther, Xu, Zhenhua, Marini, Joseph C., Pendley, Charles, Jiao, Qun, Shankar, Gopi, Marciniak, Stanley J., Cohen, Stanley B., Rahman, Mahboob U., Baker, Daniel, Mascelli, Mary Ann, Davis, Hugh M., Everitt, Daniel E.

Get full text

Reduced inhibition by abciximab in platelets with the PlA2 polymorphism by Wheeler, Guy L., Braden, Gregory A., Bray, Paul F., Marciniak, Stanley J., Mascelli, Mary Ann, Sane, David C.

Get full text

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab by Mascelli, Mary A., Kleiman, Neal S., Marciniak, Stanley J., Damaraju, Lakshmi, Weisman, Harlan F., Jordan, Robert E.

Get full text

Therapeutic heparin concentrations augment platelet reactivity: Implications for the pharmacologic assessment of the glycoprotein IIb/IIIa antagonist abciximab by Prystowsky, Eric N., Mascelli, Mary A., Kleiman, Neal S., Marciniak, Stanley J., Damaraju, Lakshmi J., Weisman, Harlan F.

Get full text